MindWalk Holdings Corp. has published the transcript of its Second Quarter Fiscal 2026 Earnings Call, held on December 15, 2025. The event featured presentations from CEO, President & Non-Independent Director Jennifer Lynne Bath, and Chief Financial Officer Richard Scott Areglado, with participation from analysts representing Liberty Capital Investment Corporation and H.C. Wainwright & Co, LLC. During the call, management reviewed MindWalk's financial performance, strategic initiatives, and key operational highlights for the quarter. The company, formerly known as ImmunoPrecise Antibodies, emphasized its focus on advancing internal programs, including GLP1 and dengue, expanding engagement with enterprise customers, and leveraging technology for strategic growth. The CEO commented on the company's market position, stating, "This combination of technology, differentiated assets, market understanding and partnership positions MindWalk within the small group of companies that will define how AI is applied to biologics." Management also reminded participants that financial figures were discussed in Canadian dollars and highlighted the company's commitment to transparency regarding risks and uncertainties, directing stakeholders to filings with the SEC and Canadian securities regulators for further details. The full transcript can be accessed through the link below.